Innovative Pharmaceutical Biotech (HKG:0399) entered a memorandum of understanding to invest in US-based Niraxx in exchange for a majority stake, a Tuesday Hong Kong bourse filing said.
Niraxx developed SyncWell, an artificial intelligence-powered virtual health platform, and DeepSynaps, a neurotechnology service platform.
Niraxx is also in the business of integrating photobiomodulation technology into activewear and developing a computer chip that integrates advanced technologies.
The oral insulin products seller said the potential investment is part of the group's business diversification efforts.
The parties have yet to enter a formal agreement, as stated in the disclosure.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。